专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07981624B2 Methods to detect tumors using 20P1F12/TMPRSS2 expression 有权
标题翻译：使用20P1F12 / TMPRSS2表达检测肿瘤的方法
公开(公告)号：US07981624B2
公开(公告)日：2011-07-19
申请号：US12389293
申请日：2009-02-19
申请人： Daniel E. H. Afar , Rene S. Hubert , Kahan Leong , Arthur B. Raitano , Douglas Saffran , Stephen C. Mitchell , Aya Jakobovits , Mary Faris , Igor Vivanco
发明人： Daniel E. H. Afar , Rene S. Hubert , Kahan Leong , Arthur B. Raitano , Douglas Saffran , Stephen C. Mitchell , Aya Jakobovits , Mary Faris , Igor Vivanco
IPC分类号： G01N33/53
CPC分类号： C12Q1/6886 , C12Q2600/136 , C12Q2600/154 , G01N33/57419 , G01N33/57434 , G01N33/57488 , G01N2333/95
摘要： Compositions for the diagnosis and therapy of prostate and colon cancer, derived from or based on a novel prostate-specific, androgen-regulated, cell membrane associated and secreted serine protease termed 20P1F12/TMPRSS2 are described. A full length cDNA comprising the entire coding sequence of the 20P1F12/TMPRSS2 gene (also designated 20P1F12-GTC1 herein) is provided (FIG. 1). Among the compositions provided are antibodies that bind to 20P1F12/TMPRSS2 proteins and polypeptide fragments thereof, including antibodies labeled with a detectable marker or toxin or therapeutic composition. The invention also provides prognostic and diagnostic methods of examining a biological sample for evidence of disregulated cellular growth by comparing the status of 20P1F12/TMPRSS2 in the biological sample to the status of 20P1F12/TMPRSS2 in a corresponding normal sample, wherein alterations in the status of 20P1F12/TMPRSS2 in the biological sample are associated with disregulated cellular growth. The invention further provides various therapeutic compositions and strategies for treating prostate cancer, including particularly, 20P1F12/TMPRSS2 polypeptide and anti-20P1F12/TMPRSS2 antibody therapy methods and compositions, cancer vaccines, and small molecule therapy.
摘要翻译：描述了衍生自或基于称为20P1F12 / TMPRSS2的新型前列腺特异性，雄激素调节的细胞膜相关和分泌的丝氨酸蛋白酶的前列腺和结肠癌的诊断和治疗的组合物。提供了包含20P1F12 / TMPRSS2基因（本文中也称为20P1F12-GTC1）的整个编码序列的全长cDNA（图1）。所提供的组合物是结合20P1F12 / TMPRSS2蛋白和其多肽片段的抗体，包括用可检测标记或毒素或治疗组合物标记的抗体。本发明还提供了通过将生物样品中20P1F12 / TMPRSS2的状态与对应的正常样品中的20P1F12 / TMPRSS2的状态进行比较来检查生物样品以检测细胞生长失调的证据的预后和诊断方法，其中，生物样品中的20P1F12 / TMPRSS2与细胞生长失调有关。本发明还提供了治疗前列腺癌的各种治疗组合物和策略，特别包括20P1F12 / TMPRSS2多肽和抗-20P1F12 / TMPRSS2抗体治疗方法和组合物，癌症疫苗和小分子治疗。

2. 发明授权

US07037667B1 Tumor antigen useful in diagnosis and therapy of prostate and colon cancer 失效
标题翻译：肿瘤抗原可用于诊断和治疗前列腺和结肠癌
公开(公告)号：US07037667B1
公开(公告)日：2006-05-02
申请号：US09615285
申请日：2000-07-12
申请人： Daniel E. H. Afar , Rene S. Hubert , Kahan Leong , Arthur B. Raitano , Douglas Saffran , Stephen C. Mitchell , Aya Jakobovits , Mary Faris , Igor Vivanco
发明人： Daniel E. H. Afar , Rene S. Hubert , Kahan Leong , Arthur B. Raitano , Douglas Saffran , Stephen C. Mitchell , Aya Jakobovits , Mary Faris , Igor Vivanco
IPC分类号： G01N33/574 , G01N33/48 , C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/136 , C12Q2600/154 , G01N33/57419 , G01N33/57434 , G01N33/57488 , G01N2333/95
摘要： Compositions for the diagnosis and therapy of prostate and colon cancer, derived from or based on a novel prostate-specific, androgen-related, cell membrane associated and secreted serine protease termed 20P1F12/TMPRSS2 are described. A full length cDNA comprising the entire coding sequence of the 20P1F12/TMPRSS2 gene (also designated 20P1F12-GTC1 herein) is provided (FIG. 1). Among the compositions provided are antibodies that bind to 20P1F12/TMPRSS2 proteins and polypeptide fragments thereof, including antibodies labeled with a detectable marker or toxin or therapeutic composition. The invention also provides prognostic and diagnostic methods of examining a biological sample for evidence of disregulated cellular growth by comparing the status of 20P1F12/TMPRSS2 in the biological sample to the status of 20P1F12/TMPRSS2 in a corresponding normal sample, wherein alterations in the status of 20P1F12/TMPRSS2 in the biological sample are associated with disregulated cellular growth. The invention further provides various therapeutic compositions and strategies for treating prostate cancer, including particularly, 20P1F12/TMPRSS2 polypeptide and anti-20P1F12/TMPRSS2 antibody therapy methods and compositions, cancer vaccines, and small molecule therapy.
摘要翻译：描述了源自或基于名为20P1F12 / TMPRSS2的新型前列腺特异性雄激素相关的细胞膜相关和分泌的丝氨酸蛋白酶的前列腺和结肠癌的诊断和治疗的组合物。提供了包含20P1F12 / TMPRSS2基因（本文中也称为20P1F12-GTC1）的整个编码序列的全长cDNA（图1）。所提供的组合物是结合20P1F12 / TMPRSS2蛋白和其多肽片段的抗体，包括用可检测标记或毒素或治疗组合物标记的抗体。本发明还提供了通过将生物样品中20P1F12 / TMPRSS2的状态与对应的正常样品中的20P1F12 / TMPRSS2的状态进行比较来检查生物样品以检测细胞生长失调的证据的预后和诊断方法，其中，生物样品中的20P1F12 / TMPRSS2与细胞生长失调有关。本发明还提供了治疗前列腺癌的各种治疗组合物和策略，特别包括20P1F12 / TMPRSS2多肽和抗-20P1F12 / TMPRSS2抗体治疗方法和组合物，癌症疫苗和小分子治疗。

3. 发明申请

US20090226921A1 METHODS TO DETECT TUMORS USING 20P1F12/TMPRSS2 EXPRESSION 有权
标题翻译：使用20P1F12 / TMPRSS2表达检测肿瘤的方法
公开(公告)号：US20090226921A1
公开(公告)日：2009-09-10
申请号：US12389293
申请日：2009-02-19
申请人： Daniel E. H. AFAR , Rene S. Hubert , Kahan Leong , Arthur B. Raitano , Douglas Saffran , Stephen C. Mitchell , Aya Jakobovits , Mary Faris , Igor Vivanco
发明人： Daniel E. H. AFAR , Rene S. Hubert , Kahan Leong , Arthur B. Raitano , Douglas Saffran , Stephen C. Mitchell , Aya Jakobovits , Mary Faris , Igor Vivanco
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/136 , C12Q2600/154 , G01N33/57419 , G01N33/57434 , G01N33/57488 , G01N2333/95
摘要： Compositions for the diagnosis and therapy of prostate and colon cancer, derived from or based on a novel prostate-specific, androgen-regulated, cell membrane associated and secreted serine protease termed 20P1F12/TMPRSS2 are described. A full length cDNA comprising the entire coding sequence of the 20P1F12/TMPRSS2 gene (also designated 20P1F12-GTC1 herein) is provided (FIG. 1). Among the compositions provided are antibodies that bind to 20P1F12/TMPRSS2 proteins and polypeptide fragments thereof, including antibodies labeled with a detectable marker or toxin or therapeutic composition. The invention also provides prognostic and diagnostic methods of examining a biological sample for evidence of disregulated cellular growth by comparing the status of 20P1F12/TMPRSS2 in the biological sample to the status of 20P1F12/TMPRSS2 in a corresponding normal sample, wherein alterations in the status of 20P1F12/TMPRSS2 in the biological sample are associated with disregulated cellular growth. The invention further provides various therapeutic compositions and strategies for treating prostate cancer, including particularly, 20P1F12/TMPRSS2 polypeptide and anti-20P1F12/TMPRSS2 antibody therapy methods and compositions, cancer vaccines, and small molecule therapy.
摘要翻译：描述了衍生自或基于称为20P1F12 / TMPRSS2的新型前列腺特异性，雄激素调节的细胞膜相关和分泌的丝氨酸蛋白酶的前列腺和结肠癌的诊断和治疗的组合物。提供了包含20P1F12 / TMPRSS2基因（本文中也称为20P1F12-GTC1）的整个编码序列的全长cDNA（图1）。所提供的组合物是结合20P1F12 / TMPRSS2蛋白和其多肽片段的抗体，包括用可检测标记或毒素或治疗组合物标记的抗体。本发明还提供了通过将生物样品中20P1F12 / TMPRSS2的状态与对应的正常样品中的20P1F12 / TMPRSS2的状态进行比较来检查生物样品以检测细胞生长失调的证据的预后和诊断方法，其中，生物样品中的20P1F12 / TMPRSS2与细胞生长失调有关。本发明还提供了治疗前列腺癌的各种治疗组合物和策略，特别包括20P1F12 / TMPRSS2多肽和抗-20P1F12 / TMPRSS2抗体治疗方法和组合物，癌症疫苗和小分子治疗。

4. 发明授权

US08241626B2 Serpentine transmembrane antigens expressed in human cancers and uses thereof 有权
标题翻译：人类癌症中表达的蛇纹石跨膜抗原及其用途
公开(公告)号：US08241626B2
公开(公告)日：2012-08-14
申请号：US11542758
申请日：2006-10-03
申请人： Rene S. Hubert , Arthur B. Raitano , Douglas Saffran , Daniel E. H. Afar , Steven Chappell Mitchell , Mary Faris , Aya Jakobovits
发明人： Rene S. Hubert , Arthur B. Raitano , Douglas Saffran , Daniel E. H. Afar , Steven Chappell Mitchell , Mary Faris , Aya Jakobovits
IPC分类号： A61K39/395 , A61K39/00 , C12P21/00
CPC分类号： C07K16/3069 , A61K38/00 , A61K39/00 , A61K51/1072 , A61K2039/505 , C07K14/4748 , C07K14/705 , C07K16/28 , C07K2317/34 , C07K2319/00 , C07K2319/30 , C12Q1/6886 , C12Q2600/158 , G01N33/57407 , G01N33/57419 , G01N33/57423 , G01N33/57434 , G01N33/57438 , G01N33/57449 , G01N33/57484 , G01N33/57492 , G01N2333/705
摘要： Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.
摘要翻译：描述了一种新型的细胞表面蛇纹石跨膜抗原家族。该家族中的两个蛋白质完全或主要地在前列腺中表达，也包括在前列腺癌中，因此该家族成员被称为“STEAP”（前列腺的六跨膜上皮抗原）。本文描述和表征了四种特定的人STEAP。人类STEAP在其中表现出高度的结构保守性，但与任何已知的人类蛋白质没有显着的结构同源性。 STEAP家族的原型成员STEAP-1似乎是主要在正常人体组织中的前列腺细胞中表达的IIIa型膜蛋白。在结构上，STEAP-1是一种339个氨基酸的蛋白质，其特征在于六个跨膜结构域和细胞内N-和C-末端的分子拓扑结构，表明它以“蛇纹石”的方式折叠成三个胞外和两个细胞内环。

5. 发明授权

US07947459B2 Serpentine transmembrane antigens expressed in human cancers and uses thereof 有权
标题翻译：在人类癌症中表达的蛇纹石跨膜抗原及其用途
公开(公告)号：US07947459B2
公开(公告)日：2011-05-24
申请号：US10753195
申请日：2004-01-06
申请人： Rene S. Hubert , Arthur B. Raitano , Douglas Saffran , Daniel E. H. Afar , Steven Chappell Mitchell , Mary Faris , Aya Jakobovits
发明人： Rene S. Hubert , Arthur B. Raitano , Douglas Saffran , Daniel E. H. Afar , Steven Chappell Mitchell , Mary Faris , Aya Jakobovits
IPC分类号： G01N33/53 , G01N33/567 , C07K16/00 , C12P21/08 , G01N33/574
CPC分类号： C07K16/3069 , A61K38/00 , A61K39/00 , A61K51/1072 , A61K2039/505 , C07K14/4748 , C07K14/705 , C07K16/28 , C07K2317/34 , C07K2319/00 , C07K2319/30 , C12Q1/6886 , C12Q2600/158 , G01N33/57407 , G01N33/57419 , G01N33/57423 , G01N33/57434 , G01N33/57438 , G01N33/57449 , G01N33/57484 , G01N33/57492 , G01N2333/705
摘要： Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high'degree of structural conservation among them but show no significant structural homology to any known human proteins. STEAP-2 is a 454 amino acid protein characterized by a predicted molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.
摘要翻译：描述了一种新型的细胞表面蛇纹石跨膜抗原家族。该家族中的两个蛋白质完全或主要地在前列腺中表达，也包括在前列腺癌中，因此该家族成员被称为“STEAP”（前列腺的六跨膜上皮抗原）。本文描述和表征了四种特定的人STEAP。人类STEAPs表现出高度的结构保守性，但与任何已知的人类蛋白质没有显着的结构同源性。 STEAP-2是一种454个氨基酸的蛋白质，其特征在于六个跨膜结构域和细胞内N-和C-末端的预测分子拓扑结构，表明它以“蛇纹石”的方式折叠成三个细胞外和两个细胞内环。

6. 发明授权

US07351583B2 Antibodies to G protein-coupled receptor 失效
标题翻译： G蛋白偶联受体的抗体
公开(公告)号：US07351583B2
公开(公告)日：2008-04-01
申请号：US10991028
申请日：2004-11-16
申请人： Arthur B. Raitano , Daniel E. H. Afar , Aya Jakobovits , Mary Faris , Rene S. Hubert , Steven Chappell Mitchell , Douglas Saffran
发明人： Arthur B. Raitano , Daniel E. H. Afar , Aya Jakobovits , Mary Faris , Rene S. Hubert , Steven Chappell Mitchell , Douglas Saffran
IPC分类号： C12N15/85
CPC分类号： C07K16/28 , A01K2217/05 , A61K38/00 , A61K39/00 , C07K14/705 , C07K16/3069 , C07K2317/34
摘要： A novel gene (designated PHOR-1) that is highly over-expressed in prostate and other cancers and its encoded protein are described. PHOR-1 is a G protein-coupled receptor with homology to receptors involved in olfaction. PHOR-1 in normal human tissues is restricted to prostate, and this gene is highly over-expressed in prostate cancer as well as in cancers of the kidney, uterus, cervix, stomach and rectum. Consequently, PHOR-1 provides a diagnostic and/or therapeutic target for prostate cancer.
摘要翻译：描述了在前列腺和其他癌症及其编码的蛋白质中高度过表达的新基因（称为PHOR-1）。 PHOR-1是与涉及嗅觉的受体具有同源性的G蛋白偶联受体。正常人组织中的PHOR-1仅限于前列腺，并且该基因在前列腺癌以及肾，子宫，宫颈，胃和直肠的癌症中高度过度表达。因此，PHOR-1为前列腺癌提供了诊断和/或治疗靶点。

7. 发明授权

US07208280B2 Nucleic acid and corresponding protein entitled 101P3A41 useful in treatment and detection of cancer 失效
标题翻译：核酸和相应的标题为101P3A41的蛋白质可用于治疗和检测癌症
公开(公告)号：US07208280B2
公开(公告)日：2007-04-24
申请号：US10001469
申请日：2001-10-31
申请人： Aya Jakobovits , Arthur B. Raitano , Daniel E. H. Afar , Douglas Saffran , Rene S. Hubert , Mary Faris , Pia M. Challita-Eid
发明人： Aya Jakobovits , Arthur B. Raitano , Daniel E. H. Afar , Douglas Saffran , Rene S. Hubert , Mary Faris , Pia M. Challita-Eid
IPC分类号： G01M33/53
CPC分类号： C07K14/47 , A01K2217/05 , A61K38/00 , A61K39/00 , A61K2039/505 , A61K2039/53 , C07K14/705 , C07K16/28 , C07K2317/34
摘要： A novel gene (designated 101P3A11 and also referred to as PHOR-1) and its encoded protein are described. While 101P3A11 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in prostate, colon and kidney cancers. Thus, 101P3A11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 101P3A11 gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit an immune response.
摘要翻译：描述了一种新型基因（命名为101P3A11，也称为PHOR-1）及其编码的蛋白质。虽然101P3A11在正常成人组织中表现出组织特异性表达，但在前列腺，结肠和肾癌中异常表达。因此，101P3A11为癌症提供了诊断，预后，预防和/或治疗靶点。 101P3A11基因或其片段或其编码的蛋白质或其片段可用于引发免疫应答。

8. 发明授权

US07795391B2 Protein showing enhanced expression in cancer cells 有权
标题翻译：蛋白质在癌细胞中表达增强
公开(公告)号：US07795391B2
公开(公告)日：2010-09-14
申请号：US11751621
申请日：2007-05-21
申请人： Aya Jakobovits , Arthur B. Raitano , Daniel E. H. Afar , Douglas Saffran , Rene S. Hubert , Mary Faris , Pia M. Challita-Eid
发明人： Aya Jakobovits , Arthur B. Raitano , Daniel E. H. Afar , Douglas Saffran , Rene S. Hubert , Mary Faris , Pia M. Challita-Eid
IPC分类号： C07K14/00
CPC分类号： G01N33/68 , A01K2217/05 , A61K38/00 , A61K39/00 , A61K2039/505 , A61K2039/53 , C07K14/47 , C07K14/705 , C07K16/28 , C07K2317/34 , G01N33/5017 , G01N33/57434
摘要： A novel gene (designated 101P3A11 or PHOR-1) and its encoded protein, and variants thereof, are described wherein 101P3A11 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 101P3A11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 101P3A11 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 101P3A11 can be used in active or passive immunization.
摘要翻译：描述了一种新型基因（称为101P3A11或PHOR-1）及其编码蛋白及其变体，其中101P3A11在正常成人组织中表现出组织特异性表达，并且在表I中列出的癌症中异常表达。因此，101P3A11提供诊断，预后，预防和/或治疗靶标。 101P3A11基因或其片段或其编码的蛋白质或其变体或其片段可用于引发体液或细胞免疫应答; 与101P3A11反应的抗体或T细胞可用于主动或被动免疫。

9. 发明授权

US08101372B2 Diagnosis and therapy of cancer using SGP28-related molecules 失效
标题翻译：使用SGP28相关分子诊断和治疗癌症
公开(公告)号：US08101372B2
公开(公告)日：2012-01-24
申请号：US12343170
申请日：2008-12-23
申请人： Rene S. Hubert , Arthur B. Raitano , Daniel E. H. Afar , Steve Chappell Mitchell , Mary Faris , Aya Jakobovits
发明人： Rene S. Hubert , Arthur B. Raitano , Daniel E. H. Afar , Steve Chappell Mitchell , Mary Faris , Aya Jakobovits
IPC分类号： G01N33/574
CPC分类号： G01N33/57434 , A01K2217/05 , A61K39/00 , C07K14/47 , C07K16/18 , C07K16/3069 , C07K2319/00 , C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/136 , C12Q2600/154 , C12Q2600/158
摘要： The present invention relates to methods and compositions for the diagnosis and therapy of prostate cancer which utilize isolated polynucleotides corresponding to the human SGP28 gene, proteins encoded by the SGP28 gene and fragments thereof, and antibodies capable of specifically recognizing and binding to SGP28 proteins.
摘要翻译：本发明涉及用于诊断和治疗前列腺癌的方法和组合物，其利用对应于人SGP28基因的分离的多核苷酸，由SGP28基因及其片段编码的蛋白质，以及能够特异性识别和结合SGP28蛋白质的抗体。

10. 发明授权

US07928196B2 Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer 失效
标题翻译：核酸和相应的蛋白质125P5C8可用于治疗和检测癌症
公开(公告)号：US07928196B2
公开(公告)日：2011-04-19
申请号：US12820083
申请日：2010-06-21
申请人： Mary Faris , Pia M. Challita-Eid , Rene S. Hubert , Daniel E. H. Afar , Arthur B. Raitano , Wangmao Ge , Robert Kendall Morrison , Karen Jane Meyrick Morrison , Aya Jakobovits
发明人： Mary Faris , Pia M. Challita-Eid , Rene S. Hubert , Daniel E. H. Afar , Arthur B. Raitano , Wangmao Ge , Robert Kendall Morrison , Karen Jane Meyrick Morrison , Aya Jakobovits
IPC分类号： C07K14/00
CPC分类号： C07K14/47 , A61K38/00 , A61K39/00 , Y02A50/466
摘要： A novel gene (designated 125P5C8) and its encoded protein, and variants thereof, are described wherein 125P5C8 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 125P5C8 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 125P5C8 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 125P5C8 can be used in active or passive immunization.
摘要翻译：描述了一种新型基因（称为125P5C8）及其编码的蛋白及其变体，其中125P5C8在正常成人组织中表现出组织特异性表达，并且在表I中列出的癌症中异常表达。因此，125P5C8提供诊断，预后，癌症的预防和/或治疗靶标。 125P5C8基因或其片段或其编码的蛋白质或其变体或其片段可用于引发体液或细胞免疫应答; 与125P5C8反应的抗体或T细胞可用于主动或被动免疫。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式